§ Mr. McNamaraasked the Secretary of State for Social Services how many of the manufacturing sites used by Harris Pharmaceuticals Ltd. for the production of generic medicines sold to the National Health Service were subject to inspection by the United Kingdom Medicines Inspectorate in each of the last three years; and when Harris Pharmaceuticals Ltd's manufacturing sites in South Africa were last inspected by the United Kingdom Medicines Inspectorate.
§ Mr. NewtonThe manufacturing sites used by Harris Pharmaceuticals Ltd. for products for which it holds United Kingdom product licences are largely covered by multilateral agreements which provide for inspection reports to be supplied to the United Kingdom medicines inspectorate by the licensing authority of the country concerned. The remainder have been inspected by the
816W
Northern Region Income (£) Bad debts and claims abandoned (£) Health Districts Section 58 Section 65 Section 66 Section 65 Section 66 Hartlepool 8,519 31,838 15,832 — 289 North Tees 1,377 33,341 9,842 397 86 South Tees 1,444 80,661 56,752 — — East Cumbria — 92,332 15,124 — 13 South Cumbria 30 66,515 16,997 — 27 West Cumbria — 9,646 1,619 — — Darlington — 60,767 30,670 — — Durham — 17,174 18,391 — 122 North West Durham — 28,329 7,550 6 429 South West Durham — 9,617 5,577 — 413 Northumberland — 50,704 10,207 — 48 Gateshead — 4,692 8,490 89 258 United Kingdom medicines inspectorate or are scheduled for a visit within the next 12 months. All South African manufacturing sites named as possible sources of supply for Harris Pharmaceuticals Ltd. were inspected by United Kingdom medicines inspectors in the last 16 months. The frequency of inspection is a matter for the licensing authority and details of dates of individual inspections are not normally disclosed.